Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.
Clinical Study of Lu-177-JH040182 in Patients with FAP-Positive Malignancies
Phase 1
Last update: July 2
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium Lu-177 PSMA RLT and Its Effect on Patients with Advanced Prostate Cancer, RECIPROCAL Trial
Phase 3
A Phase Ib/II Open-label Study of AMO959 with Lutetium (Lu-177) Vipivotide Tetraxetan (AAA617) in Combination with ARPI in Adult Participants with PSMA-positive mCRPC
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu-177 Dotatate), Compared to Lutetium Lu-177 Dotatate Alone for Metastatic Neuroendocrine Tumors
Phase 2
Lu-177-PSMA-617 Combined with Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial (IUNU-PC-123)
Phase 4
Last update: July 1
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated with an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
N/A
Last update: June 30
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination with Durvalumab and Bevacizumab Therapy in People with Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial